Venatorx Pharmaceuticals to Present Data at IDWeek 2021

MALVERN, Pa.–(BUSINESS WIRE)–Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

Session A1. Novel Antimicrobial Agents

• Oral Presentation #133 – ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam. A.R. Mack, C. Bethel, S. Marshall, R. Patel, D. van Duin, V.G. Fowler, D.D. Rhoads, M. Jacobs, F. van den Akker, D.A. Six, G. Moeck, K.M. Papp-Wallace, R.A. Bonomo.
• Poster Presentation #1055 – ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236. A.R. Mack, C. Bethel, S. Marshall, R. Patel, D. van Duin, V.G. Fowler, D.D. Rhoads, M. Jacobs, F. van den Akker, D.A. Six, G. Moeck, K.M. Papp-Wallace, R.A. Bonomo.
• Poster Presentation #1063 – ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam. A.R. Mack, C. Bethel, S. Marshall, R. Patel, D. van Duin, V.G. Fowler, D.D. Rhoads, M. Jacobs, F. van den Akker, D.A. Six, G. Moeck, K.M. Papp-Wallace, R.A. Bonomo.

Session A3. Resistance Mechanisms

• Poster Presentation #1286 – Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC). A.R. Mack, C. Bethel, M.A. Taracilla, F. van den Akker, B.A. Miller, T. Uehara, D.A. Six, K.M. Papp-Wallace, R.A. Bonomo.

Session A4. Treatment of antimicrobial resistant infections

• Oral Presentation #203 – Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection. M. Hackel, M.G. Wise, D.F. Sahm.
• Poster Presentation #1253 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance. M. Hackel, M.G. Wise, D.F. Sahm.
• Poster Presentation #1293 – In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020. M. Hackel, M.G. Wise, D.F. Sahm.

Session D1. Diagnostics: Bacteriology/mycobacteriology

• Poster Presentation #642 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A multicenter evaluation. V. Gupta, K. Yu, J.M. Pogue, C.J. Clancy.

Session N10. Healthcare-Associated Infections: Gram-Negatives (MDR-GNR)

• Poster Presentation #786 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) from 2016-2019: A multicenter evaluation. V. Gupta, K. Yu, J.M. Pogue, J. Weeks, C.J. Clancy.

About Venatorx Pharmaceuticals, Inc.

Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics. For more information about Venatorx, please visit www.venatorx.com.

Contacts

MEDIA CONTACT:
Heather Hunter

Vice President, Communications

hunter(at)venatorx(dot)com

484.329.8327